Compare Novartis AG (NVS) vs Impinj Inc (PI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Impinj Inc — how do they compare? Novartis AG trades at $143.75 (market cap $268.57B), while Impinj Inc trades at $189.55 (market cap $5.60B). The key difference: Novartis AG is far larger — about 48× Impinj Inc's market cap, and Novartis AG pays a 3.31% dividend while Impinj Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Impinj Inc for 22 Days on average.
| NVS | PI | |
|---|---|---|
Market Cap | $268.57B | $5.60B |
Volume | 1,532,573 | 9,929 |
Sector | Health | Technology |
52-Week High | $168.62 | $241.91 |
52-Week Low | $121.80 | $91.34 |
Typical Hold Time | 82 Days | 22 Days |
Enterprise Value | $309.89B | $5.73B |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVS trades at $143.11, down 0.12% on the day, with a bearish technical signal and mixed earnings history including a recent Q1 2026 miss. The company maintains strong profitability with a 22.5% net income margin and 30.55% ROE, while recent news highlights a major $7.8B licensing deal with China's Abogen and ongoing investor scrutiny following clinical trial setbacks.
The outlook is cautious; analyst consensus is a Hold with a $146 price target, but risks include pipeline disappointments and M&A execution. Upside hinges on successful drug launches and deal integration, while downside stems from competitive pressures and regulatory challenges.
Impinj (PI) trades at $183.37, down 4.01% today, with strong analyst support (16 Buy, 0 Sell) and a $178.83 consensus target. Recent Q2 2026 earnings beat expectations ($0.86 vs. $0.795), but the company remains unprofitable with a -7.26% net margin. Technical indicators show a bullish trend, with support at $181 and resistance at $188. The stock is positioned near its pivot point of $185 amid ongoing operational growth in RFID technology.
Outlook: PI offers growth potential in RFID markets, but profitability concerns and high valuations (P/S 14.83, EV/EBITDA 523.68) pose risks. Investors should weigh strong revenue trends against negative margins and monitor Q3 2026 results for sustained execution. Near-term price action may hinge on technical support levels and institutional sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →
